MX378409B - Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa. - Google Patents

Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.

Info

Publication number
MX378409B
MX378409B MX2016007376A MX2016007376A MX378409B MX 378409 B MX378409 B MX 378409B MX 2016007376 A MX2016007376 A MX 2016007376A MX 2016007376 A MX2016007376 A MX 2016007376A MX 378409 B MX378409 B MX 378409B
Authority
MX
Mexico
Prior art keywords
alpha
kinase inhibitor
isomorphic
dosage regimen
compound
Prior art date
Application number
MX2016007376A
Other languages
English (en)
Other versions
MX2016007376A (es
Inventor
Christian Rene Schnell
Christine Fritsch
Cristian Massacesi
Tomaso Emmanuelle Di
Marie- Caroline GERMA
Ranjana Tavorath
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX378409(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016007376A publication Critical patent/MX2016007376A/es
Publication of MX378409B publication Critical patent/MX378409B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención hace referencia a un compuesto inhibidor selectivo de la isomorfo alfa de la fosfatidilinositol 3-quinasa de formula (I) o una sal farmacéuticamente aceptable del mismo, para su uso en métodos útiles que tratan o previenen una enfermedad proliferativa en pacientes en necesidad del mismo mediante la administración oral de una cantidad terapéuticamente efectiva de dicho compuesto por al menos dos ciclos de cinco días consecutivos, en donde dicho compuesto no es administrado al paciente por un periodo de alrededor de dos días o alrededor de tres días entre dicho ciclo de cinco días consecutivos.
MX2016007376A 2013-12-06 2014-12-03 Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa. MX378409B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306679 2013-12-06
PCT/IB2014/066558 WO2015083101A1 (en) 2013-12-06 2014-12-03 Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

Publications (2)

Publication Number Publication Date
MX2016007376A MX2016007376A (es) 2017-05-11
MX378409B true MX378409B (es) 2025-03-10

Family

ID=49876516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007376A MX378409B (es) 2013-12-06 2014-12-03 Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.

Country Status (22)

Country Link
US (4) US20170000778A1 (es)
EP (2) EP3076969B1 (es)
JP (1) JP2016539149A (es)
KR (1) KR20160095035A (es)
CN (1) CN105979947A (es)
AU (2) AU2014358773A1 (es)
BR (1) BR112016011811A2 (es)
CA (1) CA2930359C (es)
CL (1) CL2016001361A1 (es)
DK (1) DK3076969T3 (es)
ES (1) ES2899167T3 (es)
HU (1) HUE057092T2 (es)
IL (1) IL245709B (es)
MX (1) MX378409B (es)
PH (1) PH12016501026A1 (es)
PL (1) PL3076969T3 (es)
PT (1) PT3076969T (es)
RU (1) RU2680246C1 (es)
SI (1) SI3076969T1 (es)
TN (1) TN2016000179A1 (es)
TW (1) TWI666019B (es)
WO (1) WO2015083101A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016347881A1 (en) * 2015-11-02 2018-05-10 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
GB202010627D0 (en) * 2020-07-10 2020-08-26 Qbd (Qs-Ip) Ltd Blocking method

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
WO1988007045A1 (fr) 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
JP2766360B2 (ja) 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP0540185A1 (en) 1991-10-10 1993-05-05 Schering Corporation 4'-(N-substituted-N-oxide)staurosporine derivatives
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
CA2123096A1 (en) 1991-11-08 1993-05-13 Beat J. Knusel Compositions containing k-252 compounds for potentiation of neurotrophin activity
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5948898A (en) 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
AU668772B2 (en) 1992-08-31 1996-05-16 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by HLA-A1, and uses thereof
DE69331228D1 (en) 1992-09-21 2002-01-10 Kyowa Hakko Kogyo Kk Heilmittel für thrombozytopenia
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
CZ288182B6 (en) 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
JP3998261B2 (ja) 1993-12-23 2007-10-24 イーライ・リリー・アンド・カンパニー プロテインキナーゼｃ阻害剤
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
PT817775E (pt) 1995-03-30 2002-01-30 Pfizer Derivados de quinazolina
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU6888196A (en) 1995-08-11 1997-03-12 Yale University Glycosylated indolocarbazole synthesis
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
EP1162201B1 (en) 1995-12-08 2006-03-29 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
KR100447918B1 (ko) 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
ATE309345T1 (de) 1996-08-02 2005-11-15 Genesense Technologies Inc Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
ATE311884T1 (de) 1997-07-12 2005-12-15 Cancer Rec Tech Ltd Cyclin-abhängige-kinase inhibierende purinderivate
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
IL139934A0 (en) 1998-05-29 2002-02-10 Sugen Inc Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
EP2112167A3 (en) 1999-06-25 2010-12-22 Genentech, Inc. Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
EP1201668A4 (en) 1999-07-13 2003-05-21 Kyowa Hakko Kogyo Kk Staurosporine DERIVATIVES
ES2306306T3 (es) 1999-11-05 2008-11-01 Astrazeneca Ab Nuevos derivados de quinazolina.
JP5027369B2 (ja) * 1999-12-06 2012-09-19 ガイストリッヒ ファーマ アーゲー 腫瘍を治療する方法
HU228979B1 (en) 2000-02-15 2013-07-29 Sugen Pyrrole substituted 2-indolinone protein kinase inhibitors
PT1274718E (pt) 2000-04-12 2007-01-31 Genaera Corp Processo para a preparação de esteróis 7. alfa-hidroxi 3- aminosubstítuidos utilizando intermediários com um grupo 7. alfa-hidroxilo desprotegido
CA2413134C (en) 2000-06-30 2010-05-11 Glaxo Group Limited Quinazoline ditosylate salt compounds
EP1650203B1 (en) 2000-09-11 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Process of preparation of benzimidazol-2-yl quinolinone derivatives
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
WO2002057423A2 (en) 2001-01-16 2002-07-25 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
WO2002062826A1 (fr) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Procede de fabrication des peptides
EP1404689A1 (en) 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
KR100484504B1 (ko) 2001-09-18 2005-04-20 학교법인 포항공과대학교 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
EP1499311B1 (en) 2002-03-29 2009-11-04 Novartis Vaccines and Diagnostics, Inc. Substituted benzazoles and use thereof as raf kinase inhibitors
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004060308A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
ES2391770T3 (es) 2003-01-21 2012-11-29 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos de triptantrina para la potenciación inmune
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
PT2301531T (pt) * 2005-02-18 2018-07-30 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
KR101854484B1 (ko) * 2010-11-08 2018-05-03 노파르티스 아게 Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료에서의 2-카르복사미드 시클로아미노 우레아 유도체의 용도
RU2014101626A (ru) * 2011-06-21 2015-07-27 Новартис Аг Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
EP2601965A1 (en) * 2011-12-06 2013-06-12 Apeiron Biologics AG Compositions for preventing or treating adverse reactions of EGFR inhibition
EP2849756A1 (en) 2012-05-16 2015-03-25 Novartis AG Dosage regimen for a pi-3 kinase inhibitor

Also Published As

Publication number Publication date
HUE057092T2 (hu) 2022-04-28
JP2016539149A (ja) 2016-12-15
AU2014358773A1 (en) 2016-06-02
AU2017245292B2 (en) 2018-09-27
TWI666019B (zh) 2019-07-21
RU2680246C1 (ru) 2019-02-19
DK3076969T3 (da) 2021-11-22
CA2930359C (en) 2022-03-01
PH12016501026A1 (en) 2016-07-04
WO2015083101A1 (en) 2015-06-11
HK1223549A1 (zh) 2017-08-04
US10434092B2 (en) 2019-10-08
US20210196696A1 (en) 2021-07-01
IL245709B (en) 2021-03-25
US20180078540A1 (en) 2018-03-22
ES2899167T3 (es) 2022-03-10
PL3076969T3 (pl) 2022-01-17
EP4000619A1 (en) 2022-05-25
SI3076969T1 (sl) 2021-12-31
KR20160095035A (ko) 2016-08-10
TN2016000179A1 (en) 2017-10-06
CA2930359A1 (en) 2015-06-11
MX2016007376A (es) 2017-05-11
BR112016011811A2 (pt) 2017-08-08
AU2017245292A1 (en) 2017-11-02
CN105979947A (zh) 2016-09-28
EP3076969A1 (en) 2016-10-12
PT3076969T (pt) 2021-11-23
IL245709A0 (en) 2016-07-31
TW201609096A (zh) 2016-03-16
US20170000778A1 (en) 2017-01-05
US20200069670A1 (en) 2020-03-05
EP3076969B1 (en) 2021-09-01
CL2016001361A1 (es) 2017-02-10

Similar Documents

Publication Publication Date Title
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201790088A1 (ru) Ингибиторы syk
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
MX2013012588A (es) Inhibidores de cinasa.
PH12016502355A1 (en) Pharmaceutical composition
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
PH12016502353A1 (en) Pharmaceutical composition
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
TW201613577A (en) Pharmaceutical combinations
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
ME02405B (me) Spojevi pirazola као inhibitori sglt1
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
AR097890A1 (es) Compuestos de urea
BR112016008060A8 (pt) composto, formulação farmacêutica, processo para preparar um composto de fórmula (i), método para preparação de um composto, uso do composto ou sal farmaceuticamente aceitável do mesmo